Clinical Trial: Study Evaluating MYO-029 in Adult Muscular Dystrophy

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title:

Brief Summary: The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.

Detailed Summary:
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Current Primary Outcome: Safety assessment

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Wyeth is now a wholly owned subsidiary of Pfizer

Dates:
Date Received: February 22, 2005
Date Started: February 2005
Date Completion:
Last Updated: December 19, 2007
Last Verified: December 2007